This work outlines the synthesis of a non-emissive, cyclometalated Ir(III) complex, Ir(ppy) 2 (H 2 O) 2 + (Ir1), which elicits a rapid, long-lived phosphorescent signal when coordinated to a histidine-containing protein immobilized on the surface of a magnetic particle. Synthesis of Ir1, in high yields,is complete O/N and involves splitting of the parent cyclometalated Ir(III) chloro-bridged dimer into two equivalents of the solvated complex. To confirm specificity, several amino acids were probed for coordination activity when added to the synthesized probe, and only histidine elicited a signal response. Using BNT-II, a branched peptide mimic of the malarial biomarker Histidine Rich Protein II (pfHRP-II), the iridium probe was validated as a tool for HRP-II detection. Quenching effects were noted in the BNT-II/Ir1 titration when compared to L-Histidine/ Ir1, but these were attributed to steric hindrance and triplet state quenching. Biolayer interferometry was used to determine real-time kinetics of interaction of Ir1 with BNT-II. Once the system was optimized, the limit of detection of rcHRP-II using the probe was found to be 12.8 nM in solution. When this protein was immobilized on the surface of a 50 µm magnetic agarose particle, the limit of detection was 14.5 nM. The robust signal response of this inorganic probe, as well as its flexibility of use in solution or immobilized on a surface, can lend itself toward a variety of applications, from diagnostic use to imaging.
Introduction
Colorimetric and fluorescent labeling is an important method for the detection and tracking of biochemical molecules and processes 1, 2 . The most common fluorescent markers are low molecular weight organic dyes 3, 4 , but these molecules do not always have ideal optical properties. Fluorescent dyes are prone to photobleaching, often have small Stokes shifts, and may have overlapping excitation and emission spectra. Colorimetric labeling is often achieved by the use of enzymatic labels, which have an amplified signal useful in immunoassay quantification 5, 6 . These enzymes also have their drawbacks, including photosensitivity, reaction conditions, and short substrate shelf life. These properties tend to require immunoassays and protein labeling methods to be done under well-controlled conditions using costly reagents.
Emissive transition-metal complexes have been explored as an alternative labeling approach for biochemical detection. In particular, cyclometalated Ir(III) has been studied in the context of organic light emitting diodes (OLEDs) 7-9 oxygen sensing 10 , catalysis 11 , and protein/ cell staining [12] [13] [14] . High photostability and quantum efficiency make this class of probes a good candidate for biomolecule detection 15, 16 . It was previously found that cyclometalated Ir(III) complexes, of the form [Ir(C^N) 2 (solv) 2 ] + , irreversibly bind histidine and elicit a blue-green signal response 12, 17 . These complexes are non-emissive in the solvento state, but when histidine displaces the solvent molecules and binds to the metal center, they release an intense phosphorescent signal after long-wave UV irradiation. This signal only occurs after ligand substitution, and is the result of a triplet state electron relaxing to the ground state through the activation of metal ligand charge transfer ( 3 MLCT) and ligand centered transfer ( 3 LC) pathways 8, 15 . These complexes can potentially be used as detection probes for histidine-rich proteins.
Histidine-rich proteins and their regulation levels are important in many diseases, including liver cirrhosis, cancer, and thrombic disorders. 18 Plasmodium falciparum Histidine Rich Protein II (pfHRP-II) in particular is a well-validated biomarker for malaria parasite infection. This protein is 67 kDa and contains 34% histidine, mostly within characteristic AHHAHHAAD repeating motifs 19 . These histidine repeats can bind free metal ions 19 and heme complexes 20 in host blood. pfHRP-II is commonly detected in low-resource settings using immunochromatographic rapid diagnostic tests (RDTs), but these tests are often inaccurate due to sample conditions, low biomarker concentration, poor manufacturing standards, and antibody degradation 21 .
Metal-based phosphorescent probes such as the cyclometalated Ir(III) complexes described above are attractive options for the detection of pfHRP-II due to their selective binding of histidine and their stabile and efficient emission properties. In this paper, the use of [Ir(ppy) 2 When designing a reagent for disease diagnostics, one must keep in mind the form of patient sample as well as the physiological concentration of the biomarker. For malaria, the concentration of pfHRP-II in a patient's blood can vary from low picomolar to high nanomolar. While this assay is clinically relevant for higher levels of infection, the limit of detection needs to be improved in order to detect asymptomatic patients with low picomolar circulating pfHRP-II. In the methods outlined above, the "switch-on" signal generated by Ir1 occurs in the presence of histidine. While the malarial biomarker is rich in histidine, other serum proteins, such as human serum albumin and histidine rich glycoprotein, would elicit a signal response with the probe. This would in turn lead to false positive diagnoses. This makes the capture of the protein on the surface of the particle a beneficial step, in that the protein of interest can be rapidly extracted from a patient sample. Additionally, designing a bifunctional probe, that couples a histidine rich peptide to a robust molecular recognition element (i.e. aptamer), could add another layer of specificity to the assay. The peptide would be loaded with iridium before coupling to the aptamer. In such a design, the stable Ir1 probe can still be utilized while achieving target specificity with the aptamer. This would allow for application of the probe to detect native HRP-II in a complex matrix (i.e. plasma or whole blood) and reduce non-specific binding effects. In order to further enhance the signal of rapid diagnostic tests, the assay could be incorporated into an electrochemiluminescent (ECL) system, where pfHRP-II can be detected on the RDTs as a electrochemical readout 26 . This next generation iridium probe would greatly enhance our on-bead ELISA assay for the detection of disease biomarkers.
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